Abstract

Aim: The last standard treatment for venous thromboembolism (VTE) is oral anticoagulation with a vitamin K antagonist. Treatment with a vitamin K antagonist requires frequent monitoring of the international normalized ratio (INR), and these drugs have several disadvantages. Direct oral anticoagulants are alternative drugs to oral anti-vitamin K anticoagulants. With safer ranges, novel oral anticoagulants (NOACs) have been accepted in guidelines as drugs of choice. This study aimed to retrospectively examine the outcomes of three new-generation anticoagulant drugs in a patient group.

Methods: Two hundred eighteen adults were included in this retrospective cohort study. Patients are included in this study if they had been used any of these drugs in the past: Warfarin, low molecular weight heparin (LMWH), dabigatran, apixaban, and rivaroxaban. The study was conducted retrospectively for evaluating safety and effectiveness. Treatment charges for LMWH, warfarin, and NOAC were calculated based on info from the medical monitoring fee, approximate hospital transportation costs per INR measurement, and drug fees for 6 months.

Results: In comparison with warfarin (n: 1, 1.4%), the risk of embolism recurrence was found higher with apixaban (n: 6, 20%, RR: 14.4, OR: 17.75, 95% CI: 2.03-154.99, p=0.002) and rivaroxaban (n: 6, 19.4%, RR: 13.94, OR: 17.04, 95% CI: 1.95-148.57, p=0.003) in patient groups.

Conclusion: Compared to the literature, the rivaroxaban and apixaban groups had greater bleeding and recurrence risk in our study. This may be due to dietary habits and genetic factors.

Keywords: Factor Xa inhibitors, dabigatran etexilate, heparin, low molecular weight warfarin

Copyright and license

Copyright © 2023 The Author(s). This is an open-access article published by Bolu İzzet Baysal Training and Research Hospital under the terms of the Creative Commons Attribution License (CC BY) which permits unrestricted use, distribution, and reproduction in any medium or format, provided the original work is properly cited.

How to cite

1.
Demirel ME, Korkmaz UTK. Novel oral anticoagulants’ efficacy and safety in comparison to vitamin K antagonists and low molecular weight heparins. Northwestern Med J. 2023;3(1):23-30. https://doi.org/10.54307/NWMJ.2023.70188

References

  1. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost. 2000; 83(5): 657-60.
  2. Kan İİ, Yuksel A, Güvenç O, et al. Effect of low triiodothyronine (T3) hormone levels on atrial fibrillation development after coronary artery bypass surgery. Northwestern Med J. 2021; 1(1): 1-8. https://doi.org/10.5222/NWMJ.2021.32042
  3. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133(6 Suppl): 454S-545S. https://doi.org/10.1378/chest.08-0658
  4. Heit JA, O’Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002; 162(11): 1245-8. https://doi.org/10.1001/archinte.162.11.1245
  5. Beckman MG, Hooper WC, Critchley SE, Ortel TL. Venous thromboembolism: a public health concern. Am J Prev Med. 2010; 38(4 Suppl): S495-501. https://doi.org/10.1016/j.amepre.2009.12.017
  6. Spencer FA, Emery C, Lessard D, et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med. 2006; 21(7): 722-7. https://doi.org/10.1111/j.1525-1497.2006.00458.x
  7. Benli AR, Korkmaz UTK, Karakaya E, Köroğlu M, Aktaş H, Adahan D. Klopidogrel ve Varfarinin Birlikte Kullanımında Klopidogrele Bağlı Mukokutanöz Kanama: Olgu Sunumu. Abant Tıp Dergisi. 2018; 7(2): 41-3. https://dergipark.org.tr/tr/download/article-file/1193142
  8. Little JW. New oral anticoagulants: will they replace warfarin? Oral Surg Oral Med Oral Pathol Oral Radiol. 2012; 113(5): 575-80. https://doi.org/10.1016/j.oooo.2011.10.006
  9. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361(24): 2342-52. https://doi.org/10.1056/NEJMoa0906598
  10. Raymond J, Imbert L, Cousin T, et al. Pharmacogenetics of Direct Oral Anticoagulants: A Systematic Review. J Pers Med. 2021; 11(1): 37. https://doi.org/10.3390/jpm11010037
  11. Şengül H, Bulut A. Sağlık hizmetlerinde ödeme mekanizmaları ve teşhis ile ilişkili gruplar. Estüdam Halk Sağlığı Dergisi. 2019; 4(2): 196-209. https://doi.org/10.35232/estudamhsd.526516
  12. Hokusai-VTE Investigators, Büller HR, Décousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013; 369(15): 1406-15. https://doi.org/10.1056/NEJMoa1306638
  13. Weycker D, Li X, Wygant GD, et al. Effectiveness and safety of apixaban versus warfarin as outpatient treatment of venous thromboembolism in US clinical practice. Thromb Haemost. 2018; 118(11): 1951-61. https://doi.org/10.1055/s-0038-1673689
  14. Lee S, Anglade MW, Pham D, Pisacane R, Kluger J, Coleman CI. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation. Am J Cardiol. 2012; 110(6): 845-51. https://doi.org/10.1016/j.amjcard.2012.05.011
  15. Seaman CD, Smith KJ, Ragni MV. Cost-effectiveness of rivaroxaban versus warfarin anticoagulation for the prevention of recurrent venous thromboembolism: a U.S. perspective. Thromb Res. 2013; 132(6): 647-51. https://doi.org/10.1016/j.thromres.2013.09.015
  16. Maegdefessel L, Spin JM, Azuma J, Tsao PS. New options with dabigatran etexilate in anticoagulant therapy. Vasc Health Risk Manag. 2010; 6: 339-49. https://doi.org/10.2147/vhrm.s8942
  17. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010; 103(6): 1116-27. https://doi.org/10.1160/TH09-11-0758
  18. Merli GJ, Hollander JE, Lefebvre P, et al. Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin. J Med Econ. 2016; 19(1): 84-90. https://doi.org/10.3111/13696998.2015.1096274
  19. Voukalis C, Lip GYH, Shantsila E. Non-vitamin K oral anticoagulants versus vitamin K antagonists in the treatment of venous thromboembolic disease. Expert Opin Pharmacother. 2016; 17(15): 2033-47. https://doi.org/10.1080/14656566.2016.1232393
  20. Stevanovic J, de Jong LA, Kappelhoff BS, Dvortsin EP, Voorhaar M, Postma MJ. Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands. PLoS One. 2016; 11(10): e0163550. https://doi.org/10.1371/journal.pone.0163550